Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination with PCI-24781 in Patients with Metastatic Solid Tumors
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Abexinostat (Primary) ; Pazopanib (Primary)
- Indications Carcinoma; Ovarian cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
Most Recent Events
- 21 Mar 2025 Status changed from active, no longer recruiting to completed.
- 12 Jan 2024 Planned End Date changed from 1 Jan 2025 to 31 Dec 2024.
- 12 Jan 2024 Planned primary completion date changed from 1 Feb 2024 to 31 Jan 2024.